Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 5/2012

01-10-2012 | Lymphomas (PA Hamlin, Section Editor)

B-Cell Receptor Pathobiology and Targeting in NHL

Authors: Ines M. Macias-Perez, Ian W. Flinn

Published in: Current Oncology Reports | Issue 5/2012

Login to get access

Abstract

B-cell receptor signaling plays varied and critical roles in B-cell development, homeostasis and disease. The key players of the pathway and its many signaling modulators have been identified as well as some of the mechanisms by which the pathway is regulated. With the increased incidence of non-Hodgkin’s lymphoma in recent years, there is a clear clinical need for novel agents to offer new options in resistant disease to potentially improve outcomes in curative settings. With the tremendous insight gained in the last 2 decades from basic science research, our understanding of the pathobiology of the B-cell receptor is leading to the discovery and clinical development of many new therapeutic targets such as Syk, Bruton’s tyrosine kinase, and phosphatidylinositol 3-kinase. This review will emphasize contemporary and salient findings on novel agents targeting the B-cell receptor signaling pathway for the treatment of non-Hodgkin’s lymphoma.
Literature
1.
American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.
2.
Young RM, Hardy IR, Clarke RL, et al. Mouse models of non-Hodgkin Lymphoma reveal syk as an important therapeutic target. Blood. 2009;113:2508–16.PubMedCrossRef
3.
4.
Ysebaert L, Morschhauser F. Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. Expert Opin Investig Drugs. 2011;20:1167–74.PubMedCrossRef
5.
Jumaa H, Hendriks RW, Reth M. B-cell signaling and tumorigenesis. Annu Rev Immunol. 2005;23:415–45.PubMedCrossRef
6.
Minegishi Y, Coustan-Smith E, Rapalus L, et al. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest. 1999;104:1115–21.PubMedCrossRef
7.
Hombach J, Tsubata T, Leclercq L, et al. Molecular components of the B-cell antigen receptor complex of the IgM class. Nature. 1990;343:760–2.PubMedCrossRef
8.
Kraus M, Pao LI, Reichlin A, et al. Interference with immunoglobulin (Ig)α immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an igbeta cytoplasmic tail. J Exp Med. 2001;194:455–69.PubMedCrossRef
9.
Bannish G, Fuentes-Panana EM, Cambier JC, et al. Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med. 2001;194:1583–96.PubMedCrossRef
10.
Reichlin A, Hu Y, Meffre E, et al. B cell development is arrested at the immature B cell stage in mice carrying a mutation in the cytoplasmic domain of immunoglobulin beta. J Exp Med. 2001;193:13–23.PubMedCrossRef
11.
Clark MR, Tanaka A, Powers SE, et al. Receptors, subcellular compartments and the regulation of peripheral B cell responses: the illuminating state of energy. Mol Immunol. 2010;48:1281–6.PubMedCrossRef
12.
• Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995;378:298–302. Syk is essential to couple the BCR to distal signal transduction elements.PubMedCrossRef
13.
• Cheng AM, Rowley B, Pao W, et al. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995;378:303–6. Syk has a critical role in maintaining vascular integrity, promoting differentiation and clonal expansion of B-lineage cells.PubMedCrossRef
14.
Khan WN, Sideras P, Rosen FS, et al. The role of bruton’s tyrosine kinase in B-cell development and function in mice and man. Ann NY Acad Sci. 1995;764:27–38.PubMedCrossRef
15.
Nishizumi H, Taniuchi I, Yamanashi Y, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity. 1995;3:549–60.PubMedCrossRef
16.
Rolli V, Gallwitz M, Wossning T, et al. Amplification of B cell antigen receptor signaling by a Syk/itam positive feedback loop. Mol Cell. 2002;10:1057–69.PubMedCrossRef
17.
Cornall RJ, Goodnow CC, Cyster JG. Regulation of B cell antigen receptor signaling by the lyn/cd22/shp1 pathway. Curr Top Microbiol Immunol. 1999;244:57–68.PubMedCrossRef
18.
• Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of bruton’s tyrosine kinase in immunodeficient XID mice. Science. 1993;261:358–61. A single conserved residue within the amino terminal unique region of Btk was mutated and found to interfere with normal B cell signaling demonstrating the importance of Btk protein interaction, a rationale for targeting Btk in B-cell malignancies.PubMedCrossRef
19.
Takata M, Kurosaki T. A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma. J Exp Med. 1996;184:31–40.PubMedCrossRef
20.
Ishiai M, Kurosaki M, Pappu R, et al. BLNK required for coupling Syk to PLC gamma 2 and rac1-jnk in B cells. Immunity. 1999;10:117–25.PubMedCrossRef
21.
22.
Saijo K, Mecklenbrauker I, Santana A, et al. Protein kinase C beta controls NFkB activation in B cells through selective regulation of the IkB kinase alpha. J Exp Med. 2002;195:1647–52.PubMedCrossRef
23.
Argyriou P, Economopoulou P, Sotirios P. The role of mTOR inhibitors for the treatment of B-cell lymphomas. Adv Hematol. 2012;2012:435342.PubMed
24.
Leseux L, Hamdi SM, Saati TA, et al. Syk-dependent motor activation in follicular lymphoma cells. Blood. 2006;108:4156–62.PubMedCrossRef
25.
Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115:369–78.PubMed
26.
•• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11. By gene-expression profiling, tumor, and normal cell analyses, identified two distinct subtypes, an activated B cell-like DLBCL known as ABC subtype, and a germinal centre B-cell DLBCL, patients of which had a significantly better overall survival compared with the ABC genetic signature.PubMedCrossRef
27.
Yang C, Lu P, Lee FY, et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia. 2008;22:1755–66.PubMedCrossRef
28.
• Chen L, Monti S, Juszczynski P, et al. SyK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230–7. Using DLBCL cell lines and primary tumors the important role of Syk in driving survival signals in DLBCL is demonstrated and as a potential target using fostamatinib, a Syk inhibitor.PubMedCrossRef
29.
Rinaldi A, Kwee I, Taborelli M, et al. Geneomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132:303–16.PubMedCrossRef
30.
Friedberg J, Sharman J, Schaefer-Cutillo J, et al. Fostamatinib disodium, an oral inhibitor of Syk, is well tolerated and has significant clinical activity in diffuse large B-cell lymphoma and chronic lymphocytic leukaemia. Blood. 2008;112:Abstract 3.
31.
Pollyea DA, Smith S, Fowler N, et al. A phase I dose escalation study of the Btk inhibitor pci-32765 in relapsed and refractory B cell non-Hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay [Abstract]. Blood. 2009;114:3713.
32.
Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. PNAS. 2010;107:13075–80.PubMedCrossRef
33.
Walsh KJ, Fan S, Patel A, et al. PI3K inhibitors inhibit lymphoma growth by downregulation of MYC-dependent proliferation. Blood. 2011;114:1697.
34.
Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.PubMedCrossRef
35.
Vogt PK, Kang S, Elsliger MA, et al. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci. 2007;32:342–9.PubMedCrossRef
36.
Abubaker J, Bavi PP, Al-harbi S, et al. PIK3CA mutations are mutually exclusive with pten loss in diffuse large B-cell lymphoma. Leukemia. 2007;21:2368–70.PubMedCrossRef
37.
Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078–88.PubMedCrossRef
38.
Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase (PIK3) delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Program and abstracts of the 52nd American Society of Hematology Annual Meeting and Exposition. 2010; Orlando, Florida. [Abstract 55].
39.
• Lannutti BJ, Meadows SA, Kashishian A, et al. CAL-101, an oral p110δ selective phosphatidylinositol-3-kinase (PI3K) inhibitor for the treatment of B cell malignancies inhibits PI3K signaling, cellular viability and protective signals of the microenvironment. Blood. 2009;114:286. These data demonstrate the important of PI3K isoform-δ in regulating BCR signaling in malignant B-cells as well as the microenvironment thereby providing the rationale for the clinical development of isoform-δ inhibitors of PI3K alone or in combination for patients with hematologic malignancies.
40.
Friedberg J, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578–85.PubMedCrossRef
41.
Coutre SE, Byrd JC, Furman RR, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2011;29:6631.
42.
Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood. 2010;116:1777.
43.
Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Oxf J. 2006;17:1418–12.
44.
45.
O’Brien S, Burger JA, Blum K, et al. The Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase IB/II study. Blood. 2011;118:983.
46.
Wang L, Martin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood. 2011;118:442.
47.
Byrd JC, Furman RR, Coutre SE, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients PTS): interim results of a phase Ib/II study. J Clin Oncol. 2012;30:6507.
48.
Smith MR, Neuberg D, Flinn IW, et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011;118:3525–7.PubMedCrossRef
49.
Sharman J, de Vos S, Leonard JP, et al. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2011;118:1787.
Metadata
Title
B-Cell Receptor Pathobiology and Targeting in NHL
Authors
Ines M. Macias-Perez
Ian W. Flinn
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 5/2012
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0254-8

Other articles of this Issue 5/2012

Current Oncology Reports 5/2012 Go to the issue

Melanoma (K Margolin, Section Editor)

Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management

Lymphomas (PA Hamlin, Section Editor)

Active Immunotherapy: Current State of the Art in Vaccine Approaches for NHL

Lymphomas (PA Hamlin, Section Editor)

Novel Agents in Hodgkin Lymphoma

Melanoma (K Margolin, Section Editor)

Screening and Prevention Measures for Melanoma: Is There a Survival Advantage?

Lymphomas (PA Hamlin, Section Editor)

PET/CT Adapted Therapy in Hodgkin Disease: Current State of the Art and Future Directions

Lymphomas (PA Hamlin, Section Editor)

NK/T-Cell Lymphomas: Pathobiology, Prognosis and Treatment Paradigm
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits